Trial Profile

Phase 1 study assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-168

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABM 168 (Primary)
Indications Brain metastases; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors ABM Therapeutics

Most Recent Events

29 Sep 2023 New trial record
28 Sep 2023 According to ABM therapeutics media release, company announced its IND application for ABM-168, a self-developed MEK1/2 inhibitor has been approved by the National Medical Products Administration (NMPA) to conduct Phase 1 clinical trials in patients with advanced solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com